Low-dose aspirin, coxibs, and other NSAIDS: a clinical mosaic emerges.
Aspirin has been a commercial drug for over a century, although for most of this history, an understanding of its mechanism of action, as an inhibitor of cyclooxygenase (COX) activity and thus of prostanoid synthesis, was lacking. Over the past fifty years, a large number of other nonsteroidal antii...
Principais autores: | Patrono, C, Baigent, C |
---|---|
Formato: | Journal article |
Idioma: | English |
Publicado em: |
2009
|
Registros relacionados
-
Coxibs and traditional NSAIDs for pain relief - Authors' reply.
por: Bhala, N, et al.
Publicado em: (2014) -
Coxibs and traditional NSAIDs for pain relief - Authors' reply.
por: Bhala, N, et al.
Publicado em: (2014) -
Review: NSAIDs increase GI and CV events; coxibs increase mortality
por: Baigent, C
Publicado em: (2013) -
Coxibs, traditional NSAIDs and cardiovascular safety post-PRECISION: What we thought we knew then and what we think we know now
por: Patrono, C, et al.
Publicado em: (2017) -
Low-dose aspirin for the prevention of atherothrombosis.
por: Patrono, C, et al.
Publicado em: (2005)